Lupin receives approval from U.S. FDA for Formoterol Fumarate Inhalation Solution

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist® Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

Formoterol Fumarate Inhalation Solution (RLD Perforomist®) had estimated annual sales of USD 282 million in the U.S. (IQVIA MAT June 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 695.40 as compared to the previous close of Rs. 682.50. The total number of shares traded during the day was 30101 in over 2110 trades.

The stock hit an intraday high of Rs. 699.15 and intraday low of 676.80. The net turnover during the day was Rs. 20835467.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA Approval ANDA FormoterolFumarateInhalationSolution